BioXcel Therapeutics Inc (FRA:BX2)
€ 0.5724 0.0254 (4.64%) Market Cap: 25.17 Mil Enterprise Value: 68.70 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 18/100

BioXcel Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 12, 2019 / 01:30PM GMT
Release Date Price: €7.78 (+14.75%)
Geoffrey Christopher Meacham
Barclays Bank PLC, Research Division - MD & Senior Research Analyst

Right. Good morning. So the -- welcome to the first morning of the Barclays Global Healthcare Conference. My name is Geoff Meacham. I'm the Senior Biopharma Analyst here at Barclays. It's my real pleasure to have BioXcel Therapeutics presenting this morning and speaking on behalf of BioXcel is CEO, Vimal Mehta. Vimal?

Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, Secretary & Director

Thanks, Geoff. Thank you all for joining us today. I'm very excited to share BioXcel Therapeutics' story. Before I begin, I'd like to remind everybody of safe harbor statement as we will be making forward-looking statements. BioXcel Therapeutics is the first public company, we believe, that is utilizing artificial intelligence platform for developing innovative medicines in neuroscience and Immuno-oncology. Our 2 lead assets are BXCL501, which is sublingual thin-film for acute treatment of agitation. It's a 505(b)(2) development path and 701 is a orally

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot